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The scientific community has avoided using tissue samples from patients that have been exposed to systemic chemotherapy
to infer the genomic landscape of a given cancer. Esophageal adenocarcinoma is a heterogeneous, chemoresistant tumor for
which the availability and size of pretreatment endoscopic samples are limiting. This study compares whole-genome se-
quencing data obtained from chemo-naive and chemo-treated samples. The quality of whole-genomic sequencing data is
comparable across all samples regardless of chemotherapy status. Inclusion of samples collected post-chemotherapy in-
creased the proportion of late-stage tumors. When comparing matched pre- and post-chemotherapy samples from 10 cases,
the mutational signatures, copy number, and SNV mutational profiles reflect the expected heterogeneity in this disease.
Analysis of SNVs in relation to allele-specific copy-number changes pinpoints the common ancestor to a point prior to che-
motherapy. For cases in which pre- and post-chemotherapy samples do show substantial differences, the timing of the diver-
gence is near-synchronous with endoreduplication. Comparison across a large prospective cohort (62 treatment-naive, 58
chemotherapy-treated samples) reveals no significant differences in the overall mutation rate, mutation signatures, specific
recurrent point mutations, or copy-number events in respect to chemotherapy status. In conclusion, whole-genome se-
quencing of samples obtained following neoadjuvant chemotherapy is representative of the genomic landscape of esoph-
ageal adenocarcinoma. Excluding these samples reduces the material available for cataloging and introduces a bias toward
the earlier stages of cancer.
[Supplemental material is available for this article.]
The incidence of esophageal adenocarcinoma (EAC) has increased
sixfold in the last 30 yr (Lepage et al. 2013). The majority of pa-
tients present with advanced disease, and the overall survival is
<15% despite advances in multimodal therapy (Jemal et al. 2011;
Masclee et al. 2014). Patients who do not have distant nodal or or-
gan metastases are considered suitable for treatment with curative
intent. This generally comprises systemic chemotherapy followed
by surgical excision. Chemotherapy has been shown to improve
survival to >30% for those entering a curative pathway and is
now an integral part of standard care either alone or in combina-
tion with radiotherapy, although the benefits of radiotherapy
are greater in esophageal squamous cell carcinoma (Medical
Research Council Oesophageal Cancer Working Group 2002;
Cunningham et al. 2006). Complete pathological response after
neoadjuvant chemotherapy is rare and constitutes <15% of all
cases, highlighting that residual cancer cells often remain after
this treatment (Sjoquist et al. 2011; Orditura et al. 2014).
Chemotherapeutic agents exert their effect by directly or indi-
rectly inducing DNA damage and cell death. In EAC, three distinct
classes of drugs are mainly used in combination: an intercalating
agent, a platinum-derivative, and an anti-metabolite (Allum
et al. 2011). Drugs such as epirubicine intercalate directly with
the DNA strand and thereby disrupt further replication in rapidly
dividing cells. Platinum drugs directly modify DNA through coor-
dinate-covalent bonds between DNA and the platinum moiety,
and the gross DNA damage is repaired via the nucleotide excision
repair pathway (NER) if intact. 5′-Fluorouracil and derivatives tar-
get DNA metabolism and result in DNA adducts, strand breaks,
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or stalled/collapsed DNA replication forks. In addition, many of
these drugs result in an increase of reactive oxygen species (ROS),
which can in turn induce DNA damage, including single-strand
DNA breaks (Woods and Turchi 2013). Hence, one might expect
to see direct effects of chemotherapeutic agents on the DNA se-
quence, and the extent might depend on the tumor responsive-
ness to treatment (Rebucci and Michiels 2013).
The mutation burden in EAC is high, with 8.0 mutations/Mb
(range 1.53–34.56/Mb) per haploid genome (Alexandrov et al.
2013). The genomic landscape appears to be complex and hetero-
geneous with a large number of point mutations occurring at very
low frequency apart from TP53 mutations, which are present in
70%–80% cases (Dulak et al. 2013; Weaver et al. 2014). Whole-ge-
nome sequencing studies and SNP arrays are providingmore detail
on large-scale chromosomal rearrangements that are common
with evidence of catastrophic events such as chromothripsis and
breakage-bridge-fusion (BFB) occuring in around one-third of pa-
tients (Dulak et al. 2013; Nones et al. 2014).
In the current study, we performed whole-genome sequenc-
ing in highly clinically annotated samples of EAC that included
chemo-naive and chemo-treated samples as part of the
International Cancer Genome Consortium (ICGC). We took the
opportunity to critically evaluate the impact of chemotherapy
on the genomic landscape. It has recently been reported from
exome data that chemotherapy imposes a bottleneck on tumor
evolution (Findlay et al. 2016). We therefore first sought to estab-
lish the genetic relationship between 10 matched pre- and post-
chemotherapy samples and the point at which the samples di-
verged. After perfoming this initial analysis, we examined the sin-
gle-nucleotide variant (SNV) spectrum, mutational/trinucleotide
context, and copy-number aberrations in a larger cohort of 58 che-
motherapy-treated and 62 chemotherapy-naive samples.
Results
Whole-genome sequencing of paired samples pre- and post-
chemotherapy
Whole-genome sequencing data were first analysed for 10 cases
from which samples were taken pre- and post-chemotherapy.
The clinical details of this cohort are shown in Supplemental
Table S1. Of these 10 cases, eight had a single sample taken before
and after neoadjuvant chemotherapy, and three hadmultiple sam-
ples taken before and after treatment.
Overall, the matched samples showed the expected range of
estimated tumor cellularity, overall ploidy, mutational signature
composition, SNV burden, and copy-number variation, including
losses of heterozygosity (LOH), as well as focal amplifications and
deletions (Supplemental Table S3). Regions of LOH, amplifica-
tions, and deletions are mostly the same pre-and post-chemother-
apy (with LOH always observed on the same allele for paired
samples). Paired samples range from being almost identical (pa-
tient 001: 97% of the genome in the same copy-number state,
95% of SNVs called in both samples) to very altered (patient 008:
27% of the genome in the same copy-number state, 23% of
SNVs called in both samples).
For each patient, we observe copy-number features present in
all tumor cells prechemotherapy that are not present post-chemo-
therapy, and vice versa. The key question is whether these differ-
ences are a consequence of the chemotherapy or simply a
reflection of heterogeneity. In seven out of nine cases (the cellular-
ity in one case is too low to call), we identify regions that have lost
heterozygosity in the prechemotherapy samples but have retained
heterozygosity in the post-chemotherapy samples. This implies that
the post-chemotherapy sample cannot have evolved from the pre-
chemotherapy sample but rather they have a shared antecedent.
It is informative to discuss the two extreme cases indicated
above in more detail (Figs. 1, 2). In patient 008, a minority of the
genomehas the same copy-number state pre- and post-chemother-
apy (Fig. 1A–C), and in addition, a minority of SNVs are observed
both pre- and post-chemotherapy (Fig. 1D). Events that are known
to be early, e.g., mutations of TP53 and LOH of key genes
(Supplemental Fig. S1), are seen to be shared, and indeed, the ma-
jority of the genome that does exhibit LOH is common to both
samples (Supplemental Table S3) and always occurs on the same al-
lele when it is common.While differentmutations are observed in
the pre- and post-chemotherapy samples, the same mutational
processes appear to be present (Figs 1E, 3), and the AAB copy-num-
ber state is the most common (Supplemental Table S3). Unlike
most of the pre- and post-samples in this cohort, themajority of fo-
cal amplifications are not shared, but convergent amplification of
the FGF region is observed in both samples (Fig. 1H,I). One can
therefore infer that clonal divergence occurred shortly after endor-
eduplication (Fig. 1F,G,J), and hence, the differences between the
two samples are attributable to events that predate chemotherapy.
Patient 001 is a very different case, with virtually no differences
pre- and post-chemotherapy (Fig. 2A–D; Supplemental Table S3).
We can see some “clonal” differences between the two samples
(Fig. 2F). “Subclonal” behavior prechemotherapy appears to be a re-
cent change from a clonal state that matched the post-chemothera-
py sample, indicating that although the two samples have diverged
only recently (Fig. 2H; Supplemental Table S2), the differences such
as they are cannot be attributed to the chemotherapy regime.
In general, when the pre- and post-chemotherapy samples
show substantial differences, the timing of the divergence of the
samples canbe traced tobeingnear-synchronous to endoreduplica-
tion. For the samples that show little difference, we can still trace
their common ancestry to a point prior to the chemotherapy and
seeno evidence in themutational signatures (Fig. 3), copynumbers
(Supplemental Table S3), or key genes (Supplemental Fig. S1) to
suggest that we are seeing anything other than the heterogeneity.
It is clear that the mutational signatures change over time
(Figs. 1–3) and that the more recent mutations are disproportion-
ately affected by factors affecting the power to detect SNVs (includ-
ing sequencing depth, genomic complexity, and cellularity).
Cautionmust therefore be taken in concluding that chemotherapy
has had an effect on the observed mutational signatures, and we
do not draw such a conclusion.
Our data suggest that differences seen pre- and post-chemo-
therapy are reflective of tumor heterogeneity and that either sam-
ple could be considered equally representative of the case.
However, from these data on a small patient cohort, we cannot
rule out the possibility of a subtle selective pressure, and in order
to address this, we require larger cohorts of pre- and post-chemo-
therapy samples, which thus form the second part of this analysis.
Systematic comparison of whole-genome sequencing data
on a large cohort of chemotherapy-naive or chemotherapy
treated samples
Our large cohort (n = 120), shown in Supplemental Fig. S2a, com-
prised 314 patients fromwhom there were 138 chemotherapy-na-
ive samples taken at endoscopic diagnosis, prior to any treatment,
or at the time of surgical resection if no neoadjuvant systemic
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chemotherapywas given, and 176 samples taken at surgery follow-
ing systemic chemotherapy. For the patients receiving chemother-
apy, samples were not available both before and after treatment in
this cohort. A further breakdown of the samples selected for the
large cohort analysis is shown in Supplemental Fig. S2b. The che-
motherapy given at all centers was in line with the United
Kingdom recommendation, comprising a platinum compound
as a backbone generally combinedwith epirubicin and a 5-fluorur-
acil derivative. Patients receiving radiotherapywere excluded in or-
der to maintain consistency across the cohorts. The details of the
study cohort are shown in Table 1.
Patients for which chemotherapy-treated samples were se-
quenced were significantly younger (P = 0.002) and, as expected,
presented at a more advanced stage of disease (P = 0.024) since,
for those patients going down curative pathways, chemotherapy
is not required for early stage tumors and patients have to be fit
enough to endure toxic therapy. Thus, 25 patients (40%) with
chemotherapy-naive samples went straight for surgery without
neoadjuvant systemic treatment and were of an earlier stage.
Histological response to neoadjuvant chemotherapy as assessed
by the Mandard regression score was documented in 78 of the
95 patients (Supplemental Table S7). Of these, 16 (21%) had
Mandard scores of one to three, indicating some degree of histo-
logical response. A score of four to five (present in the remaining
79%) indicates poor response to neoadjuvant treatment, as expect-
ed for this particular cancer. Although the chemotherapy-treated
group showed higher recurrence rates, this was not statistically sig-
nificant (P = 0.139). At the time of analysis, 50% of the patients
were alive, with no significant difference between the treated
and the chemotherapy-naive group (P = 0.361). Please note that
these statistics reflect the earlier stage cases in the chemothera-
py-naive group and are thus not reflective of the known benefit
of chemotherapy shown in randomized trials for this disease.
All cases underwent a stringent pathological review of a fro-
zen H&E section from the same sample that would be submitted
for sequencing to confirm the diagnosis and ensure that the histo-
pathological estimate of tumor cellularity exceeded 70%.Of the to-
tal cohort of n = 314 samples (n = 176 chemotherapy-treated, n =
138 treatment-naive), significantly more samples that were ex-
posed to chemotherapy failed this pathology review and were
therefore excluded (n = 98, 55.7% vs. n = 35, 25.4%; P < 0.001)
(Supplemental Fig. S2b). Of the treatment-naive samples, a higher
Figure 1. Profiling case 008 where the pre- and post-chemotherapy samples are different. (A–C) Illustrated are allele-specific copy-number states for the
22 autosomes: (A) prechemotherapy (alleles represented by colors), (B) post-chemotherapy, and (C ) the difference between the two allele-specific copy-
number profiles pre- and post-chemotherapy. Copy-number increases post- to prechemotherapy are shown outside the circle; decreases are shown inside
the circle. (D) Venn diagram showing the numbers of SNV calls shared pre- and post-chemotherapy, classified also by whether they affect coding genes. (E)
The mutational process signatures (reported in the Catalogue of Somatic Mutations in Cancer) that contribute substantially to the called SNVs are shown.
Of the shared SNVs, approximately 6000 lie within copy-number states AA, AAB, AABB, AAA, or AAAA and can confidently be categorized as early or late
(relative to their copy-number changes). The contributions for these subsets are shown also. (F ) For regions that in the prechemotherapy sample have copy-
number status AAA, we see that no SNVs unique to this sample have three copies. (G) For regions that in the post-chemotherapy sample have copy-number
status AAA, we see that no SNVs unique to this sample that have three copies. (H) Illustrated are allele-specific copy numbers for a region of Chromosome 11
in the prechemotherapy sample. (I) Illustrated are allele-specific copy numbers for a region of Chromosome 11 in the post-chemotherapy sample. (J) A
sketched likely timeline for this sample, although inherent to this type of data, the timings of losses are supposition.
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proportion of endoscopic biopsies failed the pathology review
comparedwith surgical specimens aswould be expected from their
small size (n = 33, 30.6% vs. n = 2, 6.7%; P = 0.01).
Genomic metrics of chemo-naive and chemo-treated samples
of the large cohort
The group of treatment-naive samples contained a median of
24,449 SNVs and indels (combined), with a median absolute devi-
ation (MAD) of 16,355, while the chemo-treated group had a me-
dian of 20,071 SNVs and indels (MAD= 12,223). The mutation
rates in the chemo-naive and treated groups were similar, with a
mean of 8.7 mutations/Mb for the former and 7.5 mutations/Mb
for the latter (Wilcoxon rank-sum test P-value = 0.4).
Some genes were only recurrently mutated in the chemo-
therapy treated samples, e.g., PTGES3L-AARSD1, RN7SL332P,
AC011893.3, OR4D12P, TSPAN10, PPFIA3, C15orf39, SLC27A4,
and NAA30, in at least 15% of this group. However, the top recur-
rently mutated genes that have been previously characterized for
EAC, which are more likely drivers in this cancer, were generally
mutated in a similar proportion of cases across the two cohorts
(Fig. 4; Dulak et al. 2013; Weaver et al. 2014).
The tissue samples in the two groups displayed similar pro-
portions of amplifications, deletions, and LOH regions (Wilcoxon
rank-sum test P-values >0.05) (Fig. 5; Supplemental Tables S4, S8;
Supplemental Fig. S3). Furthermore, in each group, the defined ge-
nomic characteristics were similar regardless of patient age, disease
stage, resectionmargin status (positive or negative for tumor cells),
or sample source (biopsy or resection specimen), (Supplemental
Table S5).
The effect of chemotherapy on mutational spectrum analysis
in the large cohort
EAC mutational signatures were extracted using the method pre-
sented by Alexandrov et al. (2013). A total of six mutational
Figure 2. Profiling case 001 where the pre- and post-chemotherapy samples are similar. (A) Illustrated are allele-specific copy-number states for the 22
autosomes prechemotherapy (alleles represented by colors). (B) Illustrated are allele-specific copy-number states for the 22 autosomes post-chemotherapy.
(C) Illustrating the difference between the two allele-specific copy-number profiles. Copy-number increases post- to prechemotherapy are shown outside
the circle; decreases are shown inside the circle. (D) Venn diagram showing the numbers of SNV calls shared pre- and post-chemotherapy, classified also by
whether they are transcript-affecting. (E) The mutational process signatures (reported at the Catalogue of Somatic Mutations in Cancer) that contribute
substantially to the called SNVs are shown. Of the shared SNVs, approximately 14,000 lie within copy-number states AA, AAB, AABB, AAAA, or AAAAB and
can confidently be categorized as early or late (relative to their copy-number changes). The contributions for these subsets are shown also. (F ) Illustrating
SNVs for a region that exhibits different copy-number states pre- (AABB) and post- (AAB) chemotherapy. The centers of predicted clusters for these states
are indicated. Within each sample, the copy-number state appears to be consistent in 100% of tumor cells. (G) Illustrated are SNVs for a region that dem-
onstrates subclonal copy-number behavior prechemotherapy. The two sets of expected cluster centers for clonal AABB (red) and AAABB (blue) solutions
prechemotherapy, against AAABB post-chemotherapy, are illustrated. The lack of a fourth SNV cluster is a strong indicator that this is a subclonal loss of one
copy from a previously clonal AAABB state. (H) A sketched likely timeline for this sample, although the timing of losses is supposition.
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signatures were identified, of which five have been previously
identified in EAC and other cancer types (Dulak et al. 2013;
Weaver et al. 2014). None of these five signatures have been previ-
ously associated with exposure to chemotherapy. We therefore
compared the number of mutations generated by each signature
within the two cohorts and did not observe any clear difference
(Fig. 6). A comparison of themutational signatures for the 10 pairs
of samples pre- and post-chemotherapy again showed similar non-
significant differences (Supplemental Fig. S6).
Since there was no significant overrepresentation of a partic-
ular trinucleotide in either group (Wilcoxon rank-sum test adjust-
ed P-values >0.05) (Supplemental Fig. S4), this prompted us to
repeat the analysis with a focus on C>A substitutionmutations oc-
curring at CpCdinucleotides that have been previously reported to
be associated with systemic treatment with cisplatin (Meier et al.
2014). There was a significant enrichment for the cisplatin-in-
duced mutational signature in the chemotherapy-treated cohort
(Fisher’s exact test P-value <0.0001) (Supplemental Fig. S5), in
agreement with observations by Murugaesu et al. (2015).
Discussion
In this study,wehave usedwhole-genome sequencing, incorporat-
ing a comprehensive analysis of copy number, SNVs, and muta-
tional signatures from prospectively collected samples with
stringent pathology QC but without imposing any restriction on
including samples collected from patients who had already been
treated with chemotherapy.
The first aim was to ensure that inclusion of chemotherapy-
exposed tissues did not result in poor quality samples in terms of
low cellularity, DNA quality, or sequencing metrics, and we have
demonstrated that the quality metrics were generally favorable
and resulted in the inclusion of a greater proportion of late-stage
tumors that would otherwise have been excluded. We then exam-
ined a small cohort of patients with samples collected pre- and
post-chemotherapy (n = 10) and observed a range in the degree
of genomic concordance given the extent of heterogeneity expect-
ed in this disease (Dulak et al. 2013; Nones et al. 2014;Weaver et al.
2014). For the samples within a case that showed a high degree of
similarity (e.g., IDs 002 and 001), we can trace their common an-
cestry to a point prior to the chemotherapy. On the other hand,
when the pre- and post-chemotherapy samples show substantial
differences (e.g., IDs 007, 008, and 005), the timing of the diver-
gence of the samples can be traced to being near-synchronous
with endoreduplication. When investigating the effect of chemo-
therapy on a larger scale in a cohort of 120 patients, we observe
that the genome of EAC is remarkably resistant to the effect of neo-
adjuvant chemotherapy. Indeed, there was a striking similarity
noted between chemotherapy-naive samples and those treated
with neoadjuvant chemotherapy at the level of copy-number aber-
rations, SNVs, andmutational spectra. This studywas not designed
to examine the genetic predictors of response to chemotherapy,
which requires a different experimental approach given that it is
Figure 3. Mutational signatures of mutational context for paired samples pre- and post-neaodjuvant chemotherapy. Illustrated are the numbers of
shared and unique single-nucleotide variants (SNVs) and their breakdown into 30 known signatures from COSMIC. Since inference of signatures de
novo is complicated by the nonindependence and small numbers of samples, we do not attempt to do so but rather infer the breakdown using quadratic
programmingmethods (seeMethods). For each patient, three rectangles are presented showing SNVs called prechemotherapy only (left), shared SNV calls
(center), and SNVs called post-chemotherapy only (right). The size of the rectangle indicates the number of SNVs, and the proportion of color denotes the
breakdown into signatures, as indicated in the key. Only eight signatures that make sizeable contributions are individually identified.
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generally a chemoresistant disease. Only 20% of patients in our
study showed a histopathological response (Mandard score 1–3,
based on the degree of fibrosis and proportion of tumor cells re-
maining) to chemotherapy, which is consistent with the treat-
ment response expected from the literature (Cunningham et al.
2006; Alderson et al. 2015).
To date, most large-scale sequencing efforts, including The
Cancer Genome Atlas (TCGA) and other ICGC projects, have
been confined to patients who are naive to systemic treatment.
Hence, for cancers treated with chemotherapy prior to surgical
resection (e.g., cancers of the stomach, esophagus, breast,
bladder, cervix, and lung), this has restricted the samples
available for analysis to pretreatment diagnostic biopsies that
are generally obtained via endoscopy or laparoscopy and are
challenging to work with due to their small size. Themain reason
for exclusion of samples in our cohort was low cellularity (<70%)
as determined by expert pathology review (three independent
pathologists) of a frozen section taken from the samples used
for DNA extraction. The proportion of chemotherapy-treated
samples excluded at this stage was more than twice as high as
the proportion of treatment-naive samples, and so this will po-
tentially bias selection away from those who show a good histo-
pathological response to systemic neoadjuvant treatment.
However, apart from cellularity there was no further difference
in the quality or quantity of DNA, library or sequence obtained.
In the future as technology improves, sequencing of single cells
Table 1. Demographic and pathological data of the large patient cohort (N = 120)
Naive n = 62 Treated n = 58 Total N = 120 P-value
Agea Years (IQR) 71.9 (62.0–76.7) 65.1 (57.7–69.3) 66.6 (59.8–74.6) 0.002
Gender (Male) 54 87.1% 50 86.2% 104 86.7% 1.000
UICC Stagea 1 16 25.8% 9 15.5% 25 20.8% 0.024
2 10 16.1% 7 12.1% 17 14.2%
3 31 50.0% 42 72.4% 73 60.8%
4 5 8.1% 0 0.0% 5 4.2%
Gradingb Well 1 1.7% 0 0.0% 1 0.8% 0.166
Moderate 30 50.0% 22 37.9% 52 44.1%
Poor 29 48.3% 36 62.1% 65 55.1%
Recurrenceb 22 36.7% 29 50.9% 51 43.6% 0.139
Alive 34 54.8% 26 44.8% 60 50.0% 0.361
(IQR) Interquartile range; age is given as median and IQR. Statistical analysis for homogeneity: Mann-Whitney U test for comparison of age, Fisher’s
exact test for categorical variables, P < 0.05.
aSignificant categories.
bIncomplete data in selected cases.
Figure 4. Proportion of nonsynonymous SNVs and indels in recurrently mutated genes in chemotherapy-treated and chemotherapy-naive cohorts. The
genes were selected from the top-ranking genes described in either of the Dulak et al. (2013) or Weaver et al. (2014) studies. The corresponding table
demonstrates the percentage of samples that had mutations in these selected genes.
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in cases that are highly responsive to neoadjuvant therapy may
be informative.
Our observation that the majority of EAC genomes remained
rather stable following chemotherapy is consistent with breast
cancer studies when considering those patients with chemoresist-
ant disease. For example, in a candidate gene study of 47 breast
cancer patients, Almendro et al. (2014) found that intratumor ge-
netic diversity was indicative of the tumor subtype and remained
stable in patients with only partial or no response to treatment.
Yates et al. (2015) interrogated the subclonal architecture of breast
cancer in 50 patients, of which 18 had samples taken before and
after neoadjuvant chemotherapy. In five of these patients, new
cloneswere seen in the post-chemotherapy samples with potential
driver events such as amplifications in MYC and FGFR2 and dele-
tions in RUNX1. Detailed phylogenetic reconstruction of these
five cases suggested that the treatment-resistant clones they
observed were likely to have beenmissed at the time of prechemo-
therapy sampling, and were unlikely to be the result of new sub-
clones arising during treatment.
In the context of EAC, Murugaesu et al. (2015) performed
exome sequencingon samples fromeight cases takenbefore and af-
ter chemotherapy. The extensive multiregion sampling was a
strength of this small study, and they found a positive correlation
between the degree of intra-tumoral heterogeneity and a poor re-
sponse to neoadjuvant chemotherapy, which in turn correlated
with a worse survival. Our study was performed as part of the
ICGC, which is designed to examine the landscape by virtue of ex-
amininga largenumberof tumor:normal pairs, andhence,wewere
generally unable to performmultiregional sampling. Findlay et al.
(2016) recently reported results fromtheir exomeanlaysis of 30pre-
and post-chemotherapy EAC samples, and in this study, they pur-
posefully selected cases showing a range of responses to chemo-
therapy. They associated good clinical response, as determined by
the histopathological Mandard score generated from the post-che-
motherapy surgical resection specimen,with evidence for genomic
bottlenecking as a result of chemotherapy. This is at odds with our
interpretation.
We cannot, from such a limitednumber of caseswith pre- and
post-chemotherapy samples, in such a diverse disease, separate the
potential sources of heterogeneity arising from spatial sampling,
temporal sampling, and chemotherapy unless we can make
some inference about the timing of events. It has been reported
previously that some point mutations, LOHs, and genome dupli-
cation events occur early in the cancer progression and that
Figure 5. Genomic architecture in chemotherapy-naive (n = 62) and chemotherapy-treated (n = 58) samples. (A) Total number of SNVs, (B) total number
of indels, (C) average ploidy, (D) percentage of the genome that is amplified (defined as copy number ≥2× the average ploidy), (E) percentage of the ge-
nome with deletions (defined as copy number ≤0.5× the average ploidy), and (F) percentage of the genome with LOH. No significant difference between
naive and chemo-treated groups is observed in any case. The mean ± 1 SD are highlighted in each case.
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genomic catastrophes and the accumulation of clonal diversity
may play a role. Our paired cases support these prior observations
(Nones et al. 2014).
On average, we noted that approximately a quarter of the ge-
nome had undergone LOH both pre- and post-chemotherapy in
our samples, and in all cases, with paired samples the same allele
was lost pre- and post-chemotherapy. Therefore, we infer that
LOH and then genome doubling occur early in the life history of
the cancers. The high point mutation rate associated with EAC al-
lows us to say something about the timing of genomic catastro-
phes and the establishment of clonal diversity. If large-scale
genomic rearrangements predate clonal diversity, then we expect
to see SNVs that occur after the copy-number changes but that
are shared pre- and-post chemotherapy. If the clonal diversity oc-
curs before the copy-number changes, then we would expect to
see SNVs that are unique to one sample but that predate local
copy-number changes. We see neither of these, strongly suggest-
ing that the establishment of clonal diversity and the copy-num-
ber changes are roughly concurrent. This suggests that it is not
just localized catastrophes but genome-wide changes that seem
to occur near-simultaneously. Therefore, the divergence of the
clones observed pre- and post-chemotherapy must have occurred
substantially before treatmentwas administered, and thus, chemo-
therapy cannot be responsible for the divergence. An alternative
explantion would be selective pressures for one clone out of those
available, but the larger cohorts discussed above revealed little ev-
idence of systematic selection of this kind.
Regarding the mutational signature analysis, we used the
methods of Alexandrov et al. (2013), which identified six main
SNV signatures in our data, five of which have been previously de-
scribed in EAC data sets (Dulak et al. 2013; Nones et al. 2014).
When comparing samples taken pre- and post-chemotherapy,
we observe that the signature patterns are often different between
those occurring before the copy number changes and those timed
as occurring after, but the more recent signature is consistent
between both the pre- and post-chemotherapy samples. Thus,
any apparent differences in the mutational signatures pre- and
post-chemotherapy are likely attribut-
able to cellularity-induced differences in
the power to detect the recent SNVs
that, by definition, have lower allele
fractions.
While our studywas not designed to
determine the prognostic value of geno-
mic response to chemotherapy, we ac-
knowledge that some of the samples for
which pre- and post-chemotherapy pro-
files differ the most (e.g., 007 and 008)
are some of those with the best survival.
However, we also note they are two of
the cases with the best pathological
TNM staging. Any approach to prognos-
ticate based on genomic factors (e.g., per-
haps following the results of Findlay et al.
2016) should at most temper established
prognostic factors such as these funda-
mental phenotypic characteristics.
Moreover, as discussed, some mutations
were found to be more recurrent follow-
ing chemotherapy, and this is an area
ripe for further research as the appropri-
ate cohorts become available.
In conclusion, the overall genomic profile of EAC remains
similar before and after chemotherapy. The poor survival in EAC
would support our findings that this cancer is resistant to chemo-
therapywith remarkable consistency in the genomeof the primary
tumor over time. Based on our findings, we would suggest that in-
clusion of neoadjuvant treated samples for large-scale sequencing
efforts should be considered by the sequencing community. Such
an approach will avoid biasing cohorts toward the earlier stages of
the disease and increase the number of samples available for anal-
ysis particularly in tumor types with neoadjuvant therapy regi-
mens. With the increasing recognition of the extent of epithelial
tumor heterogeneity, large-scale efforts are essential to maximize
the power of uncovering the full spectrum of mechanisms driving
tumorigenesis.
Methods
Sample collection and processing
EAC patients were recruited prospectively from 11 sites across the
UK as part of the OCCAMS (Oesophageal Clinical and Molecular
Stratification) Consortium. Patients on a palliative treatment path-
way, as well as those treated with radiotherapy, were excluded. The
studywas approved by the institutional ethics committees (RECNs
07/H0305/52, 10/H0305/1), and all patients gave written in-
formed consent.
Samples were obtained during either the diagnostic esopha-
gogastroduodenoscopy or endoscpic ultrasound procedure used
for staging and/or from the surgical resection specimen (Fig. 1).
For each patient, blood or normal squamous esophageal samples,
at least 5 cm distant from the tumor, were used as a germline refer-
ence. In 10 cases, tumor samples were taken from multiple spa-
tially distinct sites at surgery and, in two cases, also at EGD.
All tissue samples were snap-frozen in liquid nitrogen imme-
diately after collection and stored at −80°C. H&E-stained sections
from cancer samples were reviewed independently by two expert
hisptopathologists, and DNA was extracted and sequenced if tu-
mor cellularity was ≥70%. DNA was extracted from frozen
Figure 6. Mutational spectra analysis in chemotherapy-treated and chemotherapy-naive patient
groups. The most relevant signatures for each group have been identified according to the method pub-
lished by Alexandrov et al. (2013). Each bar shows the proportion of calls for the relevant signature per
sample; the bars on the far right, the cumulative proportion for each group.
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esophageal tissue using the AllPrep DNA/RNA mini kit (Qiagen)
and from blood samples using the QIAamp DNA blood maxi kit
(Qiagen) according to manufacturer’s instructions.
Whole-genome sequencing
As part of the ICGC, 100- to 125-bp paired-end sequencing was
performed under contract by Illumina to a typical depth of at least
50×, with 94% of the known genome being sequenced to at least
8× coverage while achieving a PHRED quality of at least 30 for at
least 80% of mapping bases. QC metrics were computed on a
per lane basis using FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc) and in-house tools, enabling
the identification of sequence reads that required trimming.
Technical details of the sequencing metrics are given in
Supplemental Table S2.
Mutation calling
Sequence reads were aligned to the human reference genome
(GRCh37 from Ensembl release 71) (Yates et al. 2016) using BWA
0.5.9 (Li andDurbin 2009). Aligned reads were then sorted into ge-
nome coordinate order and duplicate reads marked using Picard
1.115 (FixMateInformation and MarkDuplicates tools, respective-
ly; http://broadinstitute.github.io/picard). Somatic SNVs and
indels were detected using Strelka 1.0.13 (Saunders et al. 2012).
To increase accuracy, additional filters were applied to high-confi-
dence calls (those passing Stelka’s filters); details are given in
Supplemental Table S6. Functional annotation of the resulting var-
iants was performed using Variant Effect Predictor (VEP release 75)
(McLaren et al. 2016).
Copy-number calling
For the large cohort, absolute copy-number alterations, cellulari-
ties, and ploidies for each sample were estimated using ASCAT-
NGSv.2.1 using read counts at germlineheterozygous positions es-
timated by GATK 3.2-2 (Van Loo et al. 2010; Nik-Zainal et al.
2012). Segments were considered amplified if the ratio of absolute
copy number to ploidy exceeded two and deleted if the ratio was
less than 0.5. LOH regions were defined as regions in the genome
where the minor copy number was zero.
Mutational signature analysis
Mutational signatures were identified using the methodology de-
scribed by Alexandrov et al. (2013). Before running the software,
common variants in the 1000 Genomes database (The 1000
Genomes Project Consortium 2015) appearing in at least 0.5% of
the population were removed. The optimal number of signatures
in the data set was chosen to balance the signature stability against
the Frobenius reconstruction error. The cisplatin signature enrich-
ment analysis was performed as described by Murugaesu et al.
(2015).
Multiple sample analysis
AGATKwalker was used to identify a set of germline-heterozygous
loci for each trio. The search was restricted to the autosomes, sites
with no more than 20 germline reads were filtered by GATK
(McKenna et al. 2010), sites with germline coverage between 16
and 90 with at least four copies of each allele present, sites where
the strand bias lies between 0.1 and 0.9, and sites that are not in
obvious regions of germline copy-number variation, identified
with fastseg (Klambauer et al. 2012). This results in approximately
2 million such loci per trio. The depths of coverage and allele frac-
tions for these loci were recorded for all samples in the trio.
To aid segmentation, a running median was applied to the
depth and allele fraction data. A single segmentation of these val-
ues was created for each patient by combining, for each tumor
sample, a sliding analysis-of-variance procedure and careful man-
ual review of the genome. We erred on the side of oversegmenta-
tion as there is little to no penalty for this in the analyses that
follow. The cellularity and baseline copy number for each sample
was identified using the Crambled tool (Lynch 2015), and depth
and allele-fraction values for clonal copy-number states were pre-
dicted. Segments were assigned to these copy-number states, or
subclonal combinations of those states, based on the mean values
for the segments. Where solutions for a segment appeared to be
subclonal or differed between the multiple samples for a patient,
they were reviewed for possible technical explanations such as
missegmentation. Neighboring “segments” assigned the same
copy-number state in both samples were merged. Segments were
compared across samples to confirm the consistency of allele as-
signment (e.g., if both samples show two copies of one allele and
one copy of the other, is the same allele duplicated in both cases)
and corrected if not.
SNVs were called with Strelka and annotated with VEP as de-
scribed elsewhere. SNVs were mapped to a copy-number state pre-
and post-chemotherapy. SNVs with the same copy-number com-
bination pre- and post-chemotherapy were partitioned into early
(coming before a copy-number change) and late mutations where
copy-number states and power allowed. Vectors of trinucleotide
mutation counts were deconstructed into the 30 COSMIC signa-
tures (http://cancer.sanger.ac.uk/cosmic/signatures) using a qua-
dratic programming approach (Lynch et al. 2016).
Data access
The whole-genome sequencing data from this study have been
submitted to the European Genome-phenome Archive (EGA;
https://www.ebi.ac.uk/ega/home) under accession number
EGAD00001002241. Mutation calls can be found within the
ICGC data portal (https://dcc.icgc.org/) under project ID ESAD-
UK and library IDs listed in Supplemental Table S2.
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